Literature DB >> 33923200

Nanomedicine to Overcome Multidrug Resistance Mechanisms in Colon and Pancreatic Cancer: Recent Progress.

Raúl Ortíz1,2,3, Francisco Quiñonero1,2,3, Beatriz García-Pinel1,2,3, Marco Fuel1,3, Cristina Mesas1,2,3, Laura Cabeza1,2,3, Consolación Melguizo1,2,3, Jose Prados1,2,3.   

Abstract

The development of drug resistance is one of the main causes of cancer treatment failure. This phenomenon occurs very frequently in different types of cancer, including colon and pancreatic cancers. However, the underlying molecular mechanisms are not fully understood. In recent years, nanomedicine has improved the delivery and efficacy of drugs, and has decreased their side effects. In addition, it has allowed to design drugs capable of avoiding certain resistance mechanisms of tumors. In this article, we review the main resistance mechanisms in colon and pancreatic cancers, along with the most relevant strategies offered by nanodrugs to overcome this obstacle. These strategies include the inhibition of efflux pumps, the use of specific targets, the development of nanomedicines affecting the environment of cancer-specific tissues, the modulation of DNA repair mechanisms or RNA (miRNA), and specific approaches to damage cancer stem cells, among others. This review aims to illustrate how advanced nanoformulations, including polymeric conjugates, micelles, dendrimers, liposomes, metallic and carbon-based nanoparticles, are allowing to overcome one of the main limitations in the treatment of colon and pancreatic cancers. The future development of nanomedicine opens new horizons for cancer treatment.

Entities:  

Keywords:  PARP; cancer stem cells; colon cancer; drug resistance; miRNA; nanomedicine; pancreatic cancer; tumor microenvironment

Year:  2021        PMID: 33923200     DOI: 10.3390/cancers13092058

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  163 in total

1.  Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Treat Pancreatic Cancer with Breast Cancer 2 ( BRCA2) Mutation.

Authors:  Chong Du; Yingqiu Qi; Yinlong Zhang; Yazhou Wang; Xiao Zhao; Huan Min; Xuexiang Han; Jiayan Lang; Hao Qin; Quanwei Shi; Zhengkui Zhang; Xiaodong Tian; Greg J Anderson; Ying Zhao; Guangjun Nie; Yinmo Yang
Journal:  ACS Nano       Date:  2018-11-12       Impact factor: 15.881

2.  Superparamagnetic iron oxide nanoparticles of curcumin enhance gemcitabine therapeutic response in pancreatic cancer.

Authors:  Sheema Khan; Saini Setua; Sonam Kumari; Nirnoy Dan; Andrew Massey; Bilal Bin Hafeez; Murali M Yallapu; Zachary Edwar Stiles; Anas Alabkaa; Junming Yue; Aditya Ganju; Stephen Behrman; Meena Jaggi; Subhash C Chauhan
Journal:  Biomaterials       Date:  2019-04-08       Impact factor: 12.479

3.  Hyaluronan coated liposomes as the intravenous platform for delivery of imatinib mesylate in MDR colon cancer.

Authors:  Lalit Mohan Negi; Manu Jaggi; Vidushi Joshi; Kar Ronodip; Sushama Talegaonkar
Journal:  Int J Biol Macromol       Date:  2014-12-02       Impact factor: 6.953

4.  Selection and optimization of nano-formulation of P-glycoprotein inhibitor for reversal of doxorubicin resistance in COLO205 cells.

Authors:  Tapan K Dash; Venkata Sai Badireenath Konkimalla
Journal:  J Pharm Pharmacol       Date:  2017-04-11       Impact factor: 3.765

Review 5.  Molecular mechanisms of drug resistance.

Authors:  D B Longley; P G Johnston
Journal:  J Pathol       Date:  2005-01       Impact factor: 7.996

6.  Selection of pancreatic cancer cell-binding landscape phages and their use in development of anticancer nanomedicines.

Authors:  Deepa Bedi; James W Gillespie; Valery A Petrenko
Journal:  Protein Eng Des Sel       Date:  2014-06-04       Impact factor: 1.650

7.  Selective GPR55 antagonism reduces chemoresistance in cancer cells.

Authors:  Nagendra S Singh; Michel Bernier; Irving W Wainer
Journal:  Pharmacol Res       Date:  2016-07-14       Impact factor: 7.658

8.  A personalized and long-acting local therapeutic platform combining photothermal therapy and chemotherapy for the treatment of multidrug-resistant colon tumor.

Authors:  Beibei Wang; Sunyi Wu; Zhiqiang Lin; Yajun Jiang; Yan Chen; Zhe-Sheng Chen; Xiaoying Yang; Wei Gao
Journal:  Int J Nanomedicine       Date:  2018-12-10

9.  Therapeutic Potential of LNP-Mediated Delivery of miR-634 for Cancer Therapy.

Authors:  Kentaro Gokita; Jun Inoue; Hiroshi Ishihara; Kazuyuki Kojima; Johji Inazawa
Journal:  Mol Ther Nucleic Acids       Date:  2019-11-26       Impact factor: 8.886

10.  MicroRNA therapeutics: design of single-stranded miR-216b mimics to target KRAS in pancreatic cancer cells.

Authors:  Annalisa Ferino; Giulia Miglietta; Raffaella Picco; Stefan Vogel; Jesper Wengel; Luigi E Xodo
Journal:  RNA Biol       Date:  2018-10-11       Impact factor: 4.652

View more
  6 in total

1.  Camptothesome elicits immunogenic cell death to boost colorectal cancer immune checkpoint blockade.

Authors:  Zhiren Wang; Wenpan Li; Jonghan Park; Karina Marie Gonzalez; Aaron James Scott; Jianqin Lu
Journal:  J Control Release       Date:  2022-08-09       Impact factor: 11.467

Review 2.  Recent advances in targeted drug delivery systems for resistant colorectal cancer.

Authors:  Masoumeh Sharifi-Azad; Marziyeh Fathi; William C Cho; Abolfazl Barzegari; Hamed Dadashi; Mehdi Dadashpour; Rana Jahanban-Esfahlan
Journal:  Cancer Cell Int       Date:  2022-05-19       Impact factor: 6.429

3.  Gemcitabine-Loaded Albumin Nanoparticle Exerts An Antitumor Effect on Gemcitabine-Resistant Pancreatic Cancer Cells Induced by MDR1 and MRP1 Overexpression in Vitro.

Authors:  Lei Kong; Jiali Du; Jichun Gu; Junyuan Deng; Yujie Guo; Baian Tao; Chen Jin; Deliang Fu; Ji Li
Journal:  Front Surg       Date:  2022-05-17

4.  Identification of New Regulators of Pancreatic Cancer Cell Sensitivity to Oxaliplatin and Cisplatin.

Authors:  Vera Skripova; Ramilia Vlasenkova; Yan Zhou; Igor Astsaturov; Ramziya Kiyamova
Journal:  Molecules       Date:  2022-02-14       Impact factor: 4.411

5.  Glutathione S-Transferase Alpha 4 Promotes Proliferation and Chemoresistance in Colorectal Cancer Cells.

Authors:  Zhanhu Zhang; Lili Xu; Lin Huang; Tianqi Li; Jane Y Wang; Chunhua Ma; Xiaoyun Bian; Xiaoyan Ren; Haibo Li; Xingmin Wang
Journal:  Front Oncol       Date:  2022-07-01       Impact factor: 5.738

Review 6.  Targeting cancer stem cells with polymer nanoparticles for gastrointestinal cancer treatment.

Authors:  Yao Sun; Bo Li; Qian Cao; Tongjun Liu; Jiannan Li
Journal:  Stem Cell Res Ther       Date:  2022-10-01       Impact factor: 8.079

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.